Human Longevity, Inc. Completes 0 Million Series B Financing

SAN DIEGO, April 4, 2016 /PRNewswire/ — Human Longevity, Inc. (HLI), the genomics-based, technology-driven company, announced today that the company has completed an offering of Series B Preferred Stock, raising in excess of $220 million. HLI previously raised $80 million in its Series A offering which closed in Summer 2014.  “The closing of our Series B offering was completed with excellent results for HLI, despite especially challenging external financial markets. This is a tribute to the strength of our science, technology and team. We continue to build our business, develop life changing products and hire world class scientific, clinical and technical leaders to help us meet our goal of revolutionizing healthcare,” said J. Craig Venter, Ph.D., Co-founder and CEO, HLI.HLI is using the proceeds from this round to fund the growth…

Link to Full Article: Human Longevity, Inc. Completes 0 Million Series B Financing

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!